
Article 1 
In column 2 of the Annex to Regulation (EC) No 2380/2001, the words ‘Alpharma Belgium BVBA’ are replaced by ‘Pfizer Ltd’.
Article 2 
In column 2 of the Annex to Regulation (EC) No 1289/2004, the words ‘Alpharma (Belgium) BVBA’ are replaced by ‘Pfizer Ltd’.
Article 3 
In column 2 of the Annex to Regulation (EC) No 1455/2004, the words ‘Alpharma (Belgium) BVBA’ are replaced by ‘Pfizer Ltd’.
Article 4 
In column 2 of the Annex to Regulation (EC) No 1800/2004, the words ‘Alpharma (Belgium) BVBA’ are replaced by ‘Pfizer Ltd’.
Article 5 
In column 2 of Annex I to Regulation (EC) No 600/2005, the words ‘Alpharma (Belgium) BVBA’ are replaced by ‘Pfizer Ltd’.
Article 6 
In column 2 of the Annex to Regulation (EU) No 874/2010, the words ‘Alpharma (Belgium) BVBA’ are replaced by ‘Pfizer Ltd’.
Article 7 
In column 2 of the Annex to Implementing Regulation (EU) No 388/2011, the words ‘Alpharma (Belgium) BVBA’ are replaced by ‘Pfizer Ltd’.
Article 8 
In column 2 of Annex I to Implementing Regulation (EU) No 532/2011 the words ‘Alpharma Belgium BVBA’ are replaced by ‘Pfizer Ltd’.
Article 9 
In column 2 of the Annex to Implementing Regulation (EU) No 900/2011, the words ‘Alpharma (Belgium) BVBA’ are replaced by ‘Pfizer Ltd’.
Article 10 
Annex II to Implementing Regulation (EU) No 532/2011 is corrected in accordance with the Annex to this Regulation.
Article 11 
Existing stocks which are in conformity with the provisions applying before the date of entry into force of this Regulation may continue to be placed on the market and used until 2 September 2012.
Article 12 
This Regulation shall enter into force on the 20th day following its publication in the Official Journal of the European Union.
Article 10 and the Annex shall, however, apply from 21 June 2011.
This Regulation is binding in its entirety and directly applicable in all Member States.Done at Brussels, 10 February 2012.
For the Commission
The President
José Manuel BARROSO
ANNEX

In Annex II to Implementing Regulation (EU) No 532/2011, the Annex to Regulation (EC) No 1800/2004 as amended by Implementing Regulation (EU) No 532/2011 is corrected as follows:

((1)) in column 3 the words ‘(Cycostat 66G)’ are replaced by ‘(Robenz 66 G)’;
((2)) A new column is added:
'
800 μg robenidine hydrochloride/kg of wet liver.

350 μg robenidine hydrochloride/kg of wet kidney.

200 μg robenidine hydrochloride/kg of wet muscle.

1 300 μg robenidine hydrochloride/kg of wet skin/fat.

400 μg robenidine hydrochloride/kg of skin/fat.

400 μg robenidine hydrochloride/kg of wet liver.

200 μg robenidine hydrochloride/kg of wet kidney.

200 μg robenidine hydrochloride/kg of wet muscle.
'
